Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Atrioventricular block complete? 122 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 122 reports of Atrioventricular block complete have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.2% of all adverse event reports for PEMBROLIZUMAB.

122
Reports of Atrioventricular block complete with PEMBROLIZUMAB
0.2%
of all PEMBROLIZUMAB reports
45
Deaths
97
Hospitalizations

How Dangerous Is Atrioventricular block complete From PEMBROLIZUMAB?

Of the 122 reports, 45 (36.9%) resulted in death, 97 (79.5%) required hospitalization, and 42 (34.4%) were considered life-threatening.

Is Atrioventricular block complete Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 122 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Atrioventricular block complete?

BISOPROLOL (261) VERAPAMIL (210) METOPROLOL (209) AMLODIPINE (149) DILTIAZEM (141) RITUXIMAB (139) AMIODARONE (138) LACOSAMIDE (130) ATORVASTATIN (127) NIVOLUMAB (120)

Which PEMBROLIZUMAB Alternatives Have Lower Atrioventricular block complete Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Atrioventricular block complete Reports All Drugs Causing Atrioventricular block complete PEMBROLIZUMAB Demographics